

**Supplementary Table 3. Complete summary of results for the DNA polymerase variants identified in the eoRCC patients.**

Gene	<i>POLD1</i>	<i>POLH</i>	<i>POLE</i>	<i>POLK</i>
Variant	V759I	G209V	W1624X	E29K
$\gamma$ H2AX in patient primary PBMCs	increased		increased	increased
$\gamma$ H2AX on knockdown in Caki cells	decreased	decreased	decreased	decreased
Protein expression in EBV-cell lines	no difference	decreased	no difference	no difference
Cell counts in EBV-cell lines	no difference		no difference	no difference
CTB viability in EBV-cell lines	increased viability		increased viability	increased viability
DNA fiber assay in EBV-cell lines	slower replication speed, slower fork restoration		slower replication speed, slower fork restoration	no difference in replication
Cell cycle in EBV-cell lines	no difference		no difference	no difference
Tumor sequencing (LOH)	no LOH	no LOH	no LOH	no LOH
TMB analysis	12.85 mut/Mb		14.44 mut/Mb	-
Structural modeling	may disrupt D757 residue that coordinates Mg <sup>2+</sup> ions in the active center of the polymerase domain	may alter stability of the $\alpha$ -helix in the polymerase active center	N/A (stop gain variant)	-
Biochemical assays	less robust polymerase activity, impaired function versus wild type complex	slower lesion bypass, suggestive of better processivity over wild type	Same as above	see below
Biochemical assays previously reported	-	-	-	reduced catalytic efficiency and reduced replication fidelity versus wild type(20)

CTB – cell titer blue; DDR – DNA damage and repair; eoRCC – early-onset renal cell carcinoma; LOH – loss of heterozygosity; NS – non-significant; PBMCs – peripheral blood monocytes; TMB – tumor mutation burden